Kymera IPO Presentation Deck
KYMERA
K
Investment Highlights
Mission to discover, develop &
commercialize
transformative therapies using targeted protein
degradation (TPD)
Leading targeted protein
degradation platform
investing in unique capabilities of our
proprietary discovery platform, Pegasus
Focus on un-drugged or
inadequately-drugged targets
in clinically validated biological pathways that
TPD can potentially unlock
>>> Robust internal pipeline
focused on Oncology and Immunology with
three programs projected to enter the clinic in
2021: IRAK4, IRAKIMID and STAT3
Leveraging synergies in
biopharma
collaborations with Vertex and Sanofi to date, to
increase disease and patient impact
Experienced
management team
of leading scientific innovatorsView entire presentation